ALDH5A1 and succinic semialdehyde dehydrogenase deficiency: One such approach would be to develop an aldh5a1-/- brain-derived cell line that could be used to screen therapeutics for their ability to correct key cellular abnormalites observed in SSADHD such as GHB accumulation, oxidative stress, aberrant mitochondrial function and dysregulated gene expression.